Risk from Estimates in the Valuation of Inventories and Fixed Assets
First written in FY2021. 5 of 10 entries say "Worsened", first in FY2023-Q1. Latest entry: FY2026.
Tabaya Holdings moved to the "Worse" side of this theme in 2024.
0 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「The write-down of the carrying value of products below their acquisition cost during the current consolidated fiscal year was ¥1,347 million, an increase of ¥171 million from the previous period.」
Regarding inventory valuation and fixed asset valuation risks, the write-down of the carrying value of products increased by ¥171 million year on year to ¥1,347 million, and impairment losses also increased from ¥543 million in the previous period to ¥713 million. - FY2026-H1WorsenedAnnual report
「Current assets increased by ¥868 million, or 1.9%, from the end of the previous consolidated fiscal year to ¥45,685 million. This was mainly due to a ¥6,130 million increase in merchandise, partly offset by decreases of ¥3,721 million in cash and deposits and ¥2,359 million in accounts receivable and other receivables.」
Amid uncertainty surrounding inventory valuation and fixed asset valuation, product inventories increased by ¥6,130 million from the end of the previous period, and impairment losses for the interim period amounted to ¥426 million. - FY2025WorsenedAnnual report
「The write-down of the carrying value of products below their acquisition cost during the current consolidated fiscal year was ¥1,176 million, an increase of ¥201 million from the previous period.」
Regarding inventory valuation and fixed asset impairment risks, the write-down of the carrying value of products increased by ¥201 million year on year to ¥1,176 million, and impairment losses also increased to ¥543 million. - FY2024WorsenedAnnual report
「These estimates may be affected by future uncertain changes in economic conditions and other factors. If the actual recoverable amount differs from the estimate, this could have a material impact on the amount of impairment losses in the consolidated financial statements for the following consolidated fiscal year.」
The Company continued to disclose the uncertainty surrounding estimates for inventory valuation and fixed asset impairment. Impairment losses for the current period increased from ¥164 million in the previous period to ¥228 million. - FY2023MitigatedAnnual report
「As the spread of COVID-19 is gradually subsiding, the Company estimates the rate of sales below cost and the estimated amount of inventory to be sold based on the assumption that the recovery trend from the effects of COVID-19 on the Group's future earnings will continue from the fiscal year ending March 2024 onward.」
For inventory valuation and fixed asset impairment, the disclosure changed from assuming a prolonged impact from the pandemic to assuming a recovery trend from the fiscal year ending March 2024 onward. Impairment losses also decreased from ¥1,043 million in the previous period to ¥164 million. - FY2023-Q2RestatedAnnual report
「The Company has made accounting estimates relating to product valuation, impairment accounting for fixed assets, and the recoverability of deferred tax assets based on the assumption that the effects of the spread of COVID-19 would continue from the fiscal year ending March 2023 onward. No material changes were made to this assumption during the consolidated second quarter.」
The Company continued its accounting assumptions that the effects of the pandemic would continue from the fiscal year ending March 2023 onward, as well as its estimates for inventory valuation, impairment, and deferred tax assets, and stated that there had been no material change in the assumptions. - FY2023-Q1Extension of the period covered by the assumption of continuing effectsAnnual report
「The Company has made accounting estimates relating to product valuation, impairment accounting for fixed assets, and the recoverability of deferred tax assets based on the assumption that the effects of the spread of COVID-19 would continue from the fiscal year ending March 2023 onward.」
For inventory valuation, fixed asset impairment, and deferred tax asset estimates, the Company extended the period of its assumption that the effects of the pandemic would continue through the fiscal year ending March 2023 and beyond. - FY2022-Q3RestatedAnnual report
「Although it remains difficult to predict when the spread of COVID-19 will subside, the Group has made accounting estimates relating to product valuation, impairment accounting for fixed assets, and the recoverability of deferred tax assets based on the assumption that the effects of the spread of COVID-19 would continue from the fiscal year ending March 2022 onward. No material changes were made to this assumption during the consolidated third quarter.」
The Company continued estimating inventory valuation, fixed asset impairment, and deferred tax assets based on the assumption that the effects of the pandemic would continue from the fiscal year ending March 2022 onward, and stated that there had been no material change in the assumption. - FY2022-Q2RestatedAnnual report
「Assuming that the effects of the spread of COVID-19 would continue from the fiscal year ending March 2022 onward, the Group has made accounting estimates relating to product valuation, impairment accounting for fixed assets, and the recoverability of deferred tax assets. No material changes were made to this assumption during the consolidated second quarter.」
The Company continued estimating inventory valuation, impairment, and deferred tax assets based on the assumption that the effects of COVID-19 would continue from the fiscal year ending March 2022 onward, and stated that there had been no material change in the assumption. - FY2021First statedAnnual report
「In assessing product valuation, the Group calculates the rate of sales below cost and the estimated amount of inventory to be sold, based on forecasts of future inventory sales and other factors. If these forecasts differ from actual conditions due to changes in economic conditions or other factors, this could have a material impact on the amount by which the carrying value of products is written down in the consolidated financial statements for the following consolidated fiscal year.」
The Company disclosed inventory valuation and fixed asset impairment estimates independently as a material risk for the first time. In actual results, it recorded a ¥1,212 million write-down of the carrying value of inventories and ¥1,903 million in impairment losses.